Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy - PubMed (original) (raw)
Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy
Bahriye Aktas et al. Int J Gynecol Cancer. 2011 Jul.
Abstract
Objectives: Disseminated tumor cells (DTCs) in the bone marrow (BM) were shown to be of prognostic significance in gynecological cancers. Bone marrow aspiration is less accepted by patients compared with blood drawing. In this pilot study, we applied the AdnaTest BreastCancer based on immunomagnetic enrichment, targeting common antigens on epithelial gynecological cancers, followed by multiplex reverse transcriptase-polymerase chain reaction for selection and detection of circulating tumor cells (CTCs) in the blood of 122 ovarian cancer patients at primary diagnosis and/or after platinum-based chemotherapy. Results were compared with detection of DTC in BM.
Methods: Ten-milliliter blood was obtained before surgery (n=86) and/or after chemotherapy (n=70) and analyzed for CTC with the AdnaTest BreastCancer for the detection of EpCAM-, MUC-1-, and HER-2-transcripts. CA 125 was assessed in an additional single-plex reverse transcriptase-polymerase chain reaction. Bone marrow aspirates were analyzed in duplicate by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3.
Results: Before surgery, CTCs were detected in 19% of patients, expressing EpCAM (31%), MUC-1 (50%), HER-2 (31%), and CA 125 (50%), respectively. After chemotherapy, the overall detection rate for CTC was 27%, thereof EpCAM (68%), MUC-1 (47%), HER2 (21%), and CA 125 (37%). The overall detection rate for DTC in the BM was 35% before surgery and 31% after therapy. A comparison between DTC and CTC resulted in a concordance rate of 59% before surgery and 56% after chemotherapy. CTC positivity significantly correlated with shorter overall survival before surgery (P=0.0054) and after chemotherapy (P=0.047).
Conclusions: This methodological approach might help to identify molecular targets for specific biological therapies. Blood analysis could give additional information complimentary to that obtained by DTC.
Similar articles
- ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
Chebouti I, Kuhlmann JD, Buderath P, Weber S, Wimberger P, Bokeloh Y, Hauch S, Kimmig R, Kasimir-Bauer S. Chebouti I, et al. Oncotarget. 2017 Apr 11;8(15):24303-24313. doi: 10.18632/oncotarget.13286. Oncotarget. 2017. PMID: 28388557 Free PMC article. - Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir-Bauer S. Wimberger P, et al. Gynecol Oncol. 2007 Nov;107(2):331-8. doi: 10.1016/j.ygyno.2007.07.073. Epub 2007 Aug 31. Gynecol Oncol. 2007. PMID: 17764727 - Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Kasimir-Bauer S, et al. Breast Cancer Res. 2012 Jan 20;14(1):R15. doi: 10.1186/bcr3099. Breast Cancer Res. 2012. PMID: 22264265 Free PMC article. - Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.
Van Berckelaer C, Brouwers AJ, Peeters DJ, Tjalma W, Trinh XB, van Dam PA. Van Berckelaer C, et al. Eur J Surg Oncol. 2016 Dec;42(12):1772-1779. doi: 10.1016/j.ejso.2016.05.010. Epub 2016 May 25. Eur J Surg Oncol. 2016. PMID: 27265041 Review. - Neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Hall TR, Dizon DS. Hall TR, et al. Clin Adv Hematol Oncol. 2016 Apr;14(4):262-8. Clin Adv Hematol Oncol. 2016. PMID: 27166608 Review.
Cited by
- The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E, Huang TT, Nair JR, Zurcher G, McCoy A, Nousome D, Radke MR, Swisher EM, Lipkowitz S, Ibanez K, Donohue D, Malys T, Lee MJ, Redd B, Levy E, Rastogi S, Sato N, Trepel JB, Lee JM. Giudice E, et al. Nat Commun. 2024 Mar 30;15(1):2805. doi: 10.1038/s41467-024-47215-6. Nat Commun. 2024. PMID: 38555285 Free PMC article. Clinical Trial. - Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.
Ghose A, McCann L, Makker S, Mukherjee U, Gullapalli SVN, Erekkath J, Shih S, Mahajan I, Sanchez E, Uccello M, Moschetta M, Adeleke S, Boussios S. Ghose A, et al. Ther Adv Med Oncol. 2024 Feb 29;16:17588359241233225. doi: 10.1177/17588359241233225. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38435431 Free PMC article. Review. - High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.
Wilczyński J, Paradowska E, Wilczyński M. Wilczyński J, et al. Biomedicines. 2024 Jan 19;12(1):229. doi: 10.3390/biomedicines12010229. Biomedicines. 2024. PMID: 38275400 Free PMC article. Review. - Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives.
Zhang H, Wang L, Wu H. Zhang H, et al. Front Oncol. 2023 Dec 19;13:1276085. doi: 10.3389/fonc.2023.1276085. eCollection 2023. Front Oncol. 2023. PMID: 38169730 Free PMC article. Review. - Novel method for highly multiplexed gene expression profiling of circulating tumor cells (CTCs) captured from the blood of women with metastatic breast cancer.
Farhang Ghahremani M, Seto KKY, Cho W, Miller MC, Smith P, Englert DF. Farhang Ghahremani M, et al. J Transl Med. 2023 Jun 26;21(1):414. doi: 10.1186/s12967-023-04242-z. J Transl Med. 2023. PMID: 37365600 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous